Catyalyst Pharma (CPRX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update
August 9, 2017 4:30 PM EDTCORAL GABLES, Fla., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2017 and provided a corporate update.
We continue to make progress towards completion of enrollment in our confirmatory Phase 3 trial of Firdapse® in LEMS patients, said Patrick J. McEnany, Chief Executive Officer of Catalyst. We look forward to receiving top-line results from our Phase 3 trial, and assuming... More
